GPT-Rosalind (OpenAI) vs AI21 Jamba2

Which one should you pick? Here's the full breakdown.

GPT-Rosalind (OpenAI)

C
6.8/10

OpenAI's first domain-specific model -- life sciences, drug discovery, translational medicine. Launched 2026-04-16 as a Trusted Access research preview. Launch partners: Amgen, Moderna, Allen Institute, Thermo Fisher. Paired with a Life Sciences Codex plugin (50+ scientific tool integrations)

Our Pick

AI21 Jamba2

A
8.0/10

AI21 Labs' hybrid SSM-Transformer (Mamba-style) open-weight family -- Jamba2 launched 2026-01-08. Two sizes: 3B dense (runs on phones / laptops) and Jamba2 Mini MoE (12B active / 52B total). Apache 2.0, 256K context, mid-trained on 500B tokens

CategoryGPT-Rosalind (OpenAI)AI21 Jamba2
Ease of Use3.06.5
Output Quality9.08.0
Value7.09.0
Features8.08.5
Overall6.88.0

Pricing Comparison

FeatureGPT-Rosalind (OpenAI)AI21 Jamba2
Free TierNoYes
Starting PriceInvite only$0

Which Should You Pick?

Pick GPT-Rosalind (OpenAI) if...

  • Higher output quality (9 vs 8)

Researchers and enterprises in biology, drug discovery, protein science, translational medicine, or adjacent life-sciences domains who can get Trusted Access. Also relevant to anyone building life-sciences AI products who needs to understand where OpenAI's vertical strategy is heading.

Visit GPT-Rosalind (OpenAI)

Pick AI21 Jamba2 if...

  • Easier to use (6.5 vs 3)
  • Better value for money (9/10)
  • Has a free tier

Developers building long-context RAG systems (256K context with manageable memory is the sweet spot), mobile/edge deployments where Jamba2 3B's hybrid efficiency shines, and teams that want to experiment with non-transformer architectures while staying in Apache-2.0 territory. Also good for Israeli + EU enterprise procurement where AI21's geography / GDPR posture matters.

Visit AI21 Jamba2

Our Verdict

AI21 Jamba2 is the clear winner here with 8.0/10 vs 6.8/10. GPT-Rosalind (OpenAI) isn't bad, but AI21 Jamba2 outperforms it across the board. Pick GPT-Rosalind (OpenAI) only if researchers and enterprises in biology, drug discovery, protein science, translational medicine, or adjacent life-sciences domains who can get trusted access.